Test Price
2,800 AED✅ Home Collection Available
MSH2 Gene Mismatch Repair Cancer Syndrome Genetic Test in Dubai, UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity through ISO 9001:2015 Certified NGS processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital‑grade home collection (8 AM – 11 PM) with ISO‑certified cold‑chain transport. VIP mobile phlebotomy included.
- Clinical Guidance: Telephonic post‑test clinical guidance by a DHA‑licensed genetic counsellor to interpret your results.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The MSH2 gene mismatch repair cancer syndrome NGS test detects germline mutations in the MSH2 gene, a critical marker for Lynch syndrome (hereditary non‑polyposis colorectal cancer). This NGS‑powered analysis enables personalised cancer surveillance, risk‑reduction strategies, and informed family planning.
| Parameter | Our NGS Test (ISO‑Certified) | Standard Single‑Gene Sanger Sequencing |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) – full coding region ± deletion/duplication analysis | Sanger sequencing – point mutations only |
| Diagnostic Precision | >99.9% analytical sensitivity; detects SNVs, indels, and CNVs | ~95% sensitivity; may miss large rearrangements |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Clinical Utility | Gold‑standard Lynch syndrome diagnosis, cascade testing, and genotype‑driven surveillance | Limited; often requires reflex to MLPA for comprehensive review |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I recognise the profound impact hereditary cancer risk can have on individuals and families. This NGS test provides definitive answers, yet results must always be contextualised within a complete pedigree and clinical history. I encourage all patients to discuss findings with their oncologist or genetic counsellor before making any health decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory – Medication & Pre-Test Precautions
Do not discontinue prescribed medications without consulting your doctor. A pre-test genetic counselling session is mandatory to ensure informed consent and proper test selection.
Exclusion Criteria & Emergency Red Flags
- Allogeneic bone marrow transplant within the last 6 weeks (donor DNA interference invalidates germline analysis).
- Inability to provide informed consent or complete a pre‑test genetic counselling session.
- Red Flags – Seek immediate medical attention: Unexplained rectal bleeding, sudden change in bowel habits, unintended weight loss, or acute abdominal pain.
Patient FAQ & Clinical Guidance
1. Who should consider the MSH2 gene mismatch repair cancer syndrome NGS test?
Individuals with a personal or family history of colorectal, endometrial, or other Lynch‑associated cancers, particularly those diagnosed under age 50, should consider MSH2 genetic testing to define hereditary risk and guide life‑saving precision surveillance. The test is also invaluable for asymptomatic family members undergoing cascade screening after a known mutation is identified.
2. How is the MSH2 genetic test performed and when can I expect results?
A blood sample (whole blood or FTA card) is collected via our mobile phlebotomy service. DNA is extracted and analysed using Next‑Generation Sequencing (NGS) covering the entire coding region of MSH2. Results are available within 3 to 4 weeks, accompanied by a detailed report with clinical recommendations.
3. Can the NGS test detect all possible MSH2 mutations?
Our NGS test covers the full coding region of MSH2, including point mutations, small insertions/deletions, and copy number variations, achieving >99.9% analytical sensitivity. Rare deep intronic or promoter variants may require additional analysis, which we can coordinate if clinical suspicion persists.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
- Compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all personal health data processing.
- Adherent to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for digital health data security.
- All clinical testing and patient consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability to ensure patient safety and informed decision-making.
Clinical & Logistical Metadata
| Test Name | MSH2 Gene Mismatch Repair Cancer Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood or FTA card |
| Methodology Used | Next‑Generation Sequencing (NGS) – full coding region and deletion/duplication analysis |
| ICD-10-CM Code | Z15.09 (Genetic susceptibility to other malignant neoplasm) |
| LOINC Code | 45068-8 (MSH2 gene mutation analysis in Blood) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians